IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-alpha

Jacinta Holmes, Tin Nguyen, Dilip Ratnam, Neel Mohan Heerasing, Jane V Tehan, Sara Bonanzinga, Anouk Tara Dev, Sally Bell, Stephen Pianko, Robert Chen, Kumar Visvanathan, Rachel A Hammond, David Iser, Ferry Rusli, William Sievert, Scott Bowden, Alexander J Thompson

Research output: Contribution to journalArticleResearchpeer-review

35 Citations (Scopus)

Abstract

BACKGROUND AND AIM: IL28B genotype predicts response to pegylated interferon (peg-IFN)-based therapy in chronic hepatitis C. However, the utility of IL28B genotyping in chronic hepatitis B (CHB) cohorts treated with peg-IFN is unclear. It was investigated whether IL28B genotype is associated with peg-IFN treatment outcomes in a predominantly Asian CHB cohort. METHODS: This was a retrospective analysis of CHB patients treated with 48 weeks of peg-IFN monotherapy. IL28B genotype (rs12979860) was determined (TaqMan allelic discrimination kit). Baseline hepatitis B virus (HBV)-DNA, alanine aminotransferase, and liver histology were available. The primary end-points were HBV e antigen (HBeAg) seroconversion with HBV-DNA <2000 IU/mL 24 weeks post-therapy (HBeAg-positive patients) and HBV-DNA <2000 IU/mL 24 weeks after peg-IFN (HBeAg-negative patients). The association between IL28B genotype and peg-IFN outcomes was analyzed. RESULTS: IL28B genotype was determined for 96 patients. Eighty-eight percent were Asian, 62 were HBeAg positive, and 13 were METAVIR stage F3-4. Median follow-up time was 39.3 months. The majority of patients carried the CC IL28B genotype (84 ). IL28B genotype did not differ according to HBeAg status. The primary end-points were achieved in 27 of HBeAg-positive and 61 of HBeAg-negative patients. There was no association between IL28B genotype and the primary end-point in either group. Furthermore, there was no difference in HBeAg loss alone, HBV surface antigen, alanine aminotransferase normalization, or on-treatment HBV-DNA levels according to IL28B genotype. CONCLUSIONS: In the context of a small possible effect size and high frequency in Asian populations, IL28B genotyping is likely to have, at best, limited clinical utility for predicting peg-IFN treatment outcome for CHB patients in the Asia-Pacific region.
Original languageEnglish
Pages (from-to)861 - 866
Number of pages6
JournalJournal of Gastroenterology and Hepatology
Volume28
Issue number5
DOIs
Publication statusPublished - 2013

Cite this

Holmes, Jacinta ; Nguyen, Tin ; Ratnam, Dilip ; Heerasing, Neel Mohan ; Tehan, Jane V ; Bonanzinga, Sara ; Dev, Anouk Tara ; Bell, Sally ; Pianko, Stephen ; Chen, Robert ; Visvanathan, Kumar ; Hammond, Rachel A ; Iser, David ; Rusli, Ferry ; Sievert, William ; Bowden, Scott ; Thompson, Alexander J. / IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-alpha. In: Journal of Gastroenterology and Hepatology. 2013 ; Vol. 28, No. 5. pp. 861 - 866.
@article{bbd18da6c81e4085aef697ab3735f76b,
title = "IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-alpha",
abstract = "BACKGROUND AND AIM: IL28B genotype predicts response to pegylated interferon (peg-IFN)-based therapy in chronic hepatitis C. However, the utility of IL28B genotyping in chronic hepatitis B (CHB) cohorts treated with peg-IFN is unclear. It was investigated whether IL28B genotype is associated with peg-IFN treatment outcomes in a predominantly Asian CHB cohort. METHODS: This was a retrospective analysis of CHB patients treated with 48 weeks of peg-IFN monotherapy. IL28B genotype (rs12979860) was determined (TaqMan allelic discrimination kit). Baseline hepatitis B virus (HBV)-DNA, alanine aminotransferase, and liver histology were available. The primary end-points were HBV e antigen (HBeAg) seroconversion with HBV-DNA <2000 IU/mL 24 weeks post-therapy (HBeAg-positive patients) and HBV-DNA <2000 IU/mL 24 weeks after peg-IFN (HBeAg-negative patients). The association between IL28B genotype and peg-IFN outcomes was analyzed. RESULTS: IL28B genotype was determined for 96 patients. Eighty-eight percent were Asian, 62 were HBeAg positive, and 13 were METAVIR stage F3-4. Median follow-up time was 39.3 months. The majority of patients carried the CC IL28B genotype (84 ). IL28B genotype did not differ according to HBeAg status. The primary end-points were achieved in 27 of HBeAg-positive and 61 of HBeAg-negative patients. There was no association between IL28B genotype and the primary end-point in either group. Furthermore, there was no difference in HBeAg loss alone, HBV surface antigen, alanine aminotransferase normalization, or on-treatment HBV-DNA levels according to IL28B genotype. CONCLUSIONS: In the context of a small possible effect size and high frequency in Asian populations, IL28B genotyping is likely to have, at best, limited clinical utility for predicting peg-IFN treatment outcome for CHB patients in the Asia-Pacific region.",
author = "Jacinta Holmes and Tin Nguyen and Dilip Ratnam and Heerasing, {Neel Mohan} and Tehan, {Jane V} and Sara Bonanzinga and Dev, {Anouk Tara} and Sally Bell and Stephen Pianko and Robert Chen and Kumar Visvanathan and Hammond, {Rachel A} and David Iser and Ferry Rusli and William Sievert and Scott Bowden and Thompson, {Alexander J}",
year = "2013",
doi = "10.1111/jgh.12110",
language = "English",
volume = "28",
pages = "861 -- 866",
journal = "Journal of Gastroenterology and Hepatology",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "5",

}

Holmes, J, Nguyen, T, Ratnam, D, Heerasing, NM, Tehan, JV, Bonanzinga, S, Dev, AT, Bell, S, Pianko, S, Chen, R, Visvanathan, K, Hammond, RA, Iser, D, Rusli, F, Sievert, W, Bowden, S & Thompson, AJ 2013, 'IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-alpha', Journal of Gastroenterology and Hepatology, vol. 28, no. 5, pp. 861 - 866. https://doi.org/10.1111/jgh.12110

IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-alpha. / Holmes, Jacinta; Nguyen, Tin; Ratnam, Dilip; Heerasing, Neel Mohan; Tehan, Jane V; Bonanzinga, Sara; Dev, Anouk Tara; Bell, Sally; Pianko, Stephen; Chen, Robert; Visvanathan, Kumar; Hammond, Rachel A; Iser, David; Rusli, Ferry; Sievert, William; Bowden, Scott; Thompson, Alexander J.

In: Journal of Gastroenterology and Hepatology, Vol. 28, No. 5, 2013, p. 861 - 866.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-alpha

AU - Holmes, Jacinta

AU - Nguyen, Tin

AU - Ratnam, Dilip

AU - Heerasing, Neel Mohan

AU - Tehan, Jane V

AU - Bonanzinga, Sara

AU - Dev, Anouk Tara

AU - Bell, Sally

AU - Pianko, Stephen

AU - Chen, Robert

AU - Visvanathan, Kumar

AU - Hammond, Rachel A

AU - Iser, David

AU - Rusli, Ferry

AU - Sievert, William

AU - Bowden, Scott

AU - Thompson, Alexander J

PY - 2013

Y1 - 2013

N2 - BACKGROUND AND AIM: IL28B genotype predicts response to pegylated interferon (peg-IFN)-based therapy in chronic hepatitis C. However, the utility of IL28B genotyping in chronic hepatitis B (CHB) cohorts treated with peg-IFN is unclear. It was investigated whether IL28B genotype is associated with peg-IFN treatment outcomes in a predominantly Asian CHB cohort. METHODS: This was a retrospective analysis of CHB patients treated with 48 weeks of peg-IFN monotherapy. IL28B genotype (rs12979860) was determined (TaqMan allelic discrimination kit). Baseline hepatitis B virus (HBV)-DNA, alanine aminotransferase, and liver histology were available. The primary end-points were HBV e antigen (HBeAg) seroconversion with HBV-DNA <2000 IU/mL 24 weeks post-therapy (HBeAg-positive patients) and HBV-DNA <2000 IU/mL 24 weeks after peg-IFN (HBeAg-negative patients). The association between IL28B genotype and peg-IFN outcomes was analyzed. RESULTS: IL28B genotype was determined for 96 patients. Eighty-eight percent were Asian, 62 were HBeAg positive, and 13 were METAVIR stage F3-4. Median follow-up time was 39.3 months. The majority of patients carried the CC IL28B genotype (84 ). IL28B genotype did not differ according to HBeAg status. The primary end-points were achieved in 27 of HBeAg-positive and 61 of HBeAg-negative patients. There was no association between IL28B genotype and the primary end-point in either group. Furthermore, there was no difference in HBeAg loss alone, HBV surface antigen, alanine aminotransferase normalization, or on-treatment HBV-DNA levels according to IL28B genotype. CONCLUSIONS: In the context of a small possible effect size and high frequency in Asian populations, IL28B genotyping is likely to have, at best, limited clinical utility for predicting peg-IFN treatment outcome for CHB patients in the Asia-Pacific region.

AB - BACKGROUND AND AIM: IL28B genotype predicts response to pegylated interferon (peg-IFN)-based therapy in chronic hepatitis C. However, the utility of IL28B genotyping in chronic hepatitis B (CHB) cohorts treated with peg-IFN is unclear. It was investigated whether IL28B genotype is associated with peg-IFN treatment outcomes in a predominantly Asian CHB cohort. METHODS: This was a retrospective analysis of CHB patients treated with 48 weeks of peg-IFN monotherapy. IL28B genotype (rs12979860) was determined (TaqMan allelic discrimination kit). Baseline hepatitis B virus (HBV)-DNA, alanine aminotransferase, and liver histology were available. The primary end-points were HBV e antigen (HBeAg) seroconversion with HBV-DNA <2000 IU/mL 24 weeks post-therapy (HBeAg-positive patients) and HBV-DNA <2000 IU/mL 24 weeks after peg-IFN (HBeAg-negative patients). The association between IL28B genotype and peg-IFN outcomes was analyzed. RESULTS: IL28B genotype was determined for 96 patients. Eighty-eight percent were Asian, 62 were HBeAg positive, and 13 were METAVIR stage F3-4. Median follow-up time was 39.3 months. The majority of patients carried the CC IL28B genotype (84 ). IL28B genotype did not differ according to HBeAg status. The primary end-points were achieved in 27 of HBeAg-positive and 61 of HBeAg-negative patients. There was no association between IL28B genotype and the primary end-point in either group. Furthermore, there was no difference in HBeAg loss alone, HBV surface antigen, alanine aminotransferase normalization, or on-treatment HBV-DNA levels according to IL28B genotype. CONCLUSIONS: In the context of a small possible effect size and high frequency in Asian populations, IL28B genotyping is likely to have, at best, limited clinical utility for predicting peg-IFN treatment outcome for CHB patients in the Asia-Pacific region.

UR - http://www.ncbi.nlm.nih.gov/pubmed/23301835

U2 - 10.1111/jgh.12110

DO - 10.1111/jgh.12110

M3 - Article

VL - 28

SP - 861

EP - 866

JO - Journal of Gastroenterology and Hepatology

JF - Journal of Gastroenterology and Hepatology

SN - 0815-9319

IS - 5

ER -